Russo, A.; Pisaturo, M.; Cacace, C.; Troise, A.; Granata, G.; Grimaldi, P.; Allegorico, E.; Ambrisi, F.; Papillo, M.; Numis, F.G.;
et al. Efficacy and Safety of Sotrovimab Versus Oral Antiviral for Early Treatment in High-Risk Patients in Omicron Era: A Multicenter Retrospective Study. Pathogens 2025, 14, 216.
https://doi.org/10.3390/pathogens14030216
AMA Style
Russo A, Pisaturo M, Cacace C, Troise A, Granata G, Grimaldi P, Allegorico E, Ambrisi F, Papillo M, Numis FG,
et al. Efficacy and Safety of Sotrovimab Versus Oral Antiviral for Early Treatment in High-Risk Patients in Omicron Era: A Multicenter Retrospective Study. Pathogens. 2025; 14(3):216.
https://doi.org/10.3390/pathogens14030216
Chicago/Turabian Style
Russo, Antonio, Mariantonietta Pisaturo, Chiara Cacace, Augusta Troise, Gabriele Granata, Pierantonio Grimaldi, Enrico Allegorico, Francesca Ambrisi, Martina Papillo, Fabio Giuliano Numis,
and et al. 2025. "Efficacy and Safety of Sotrovimab Versus Oral Antiviral for Early Treatment in High-Risk Patients in Omicron Era: A Multicenter Retrospective Study" Pathogens 14, no. 3: 216.
https://doi.org/10.3390/pathogens14030216
APA Style
Russo, A., Pisaturo, M., Cacace, C., Troise, A., Granata, G., Grimaldi, P., Allegorico, E., Ambrisi, F., Papillo, M., Numis, F. G., & Coppola, N.
(2025). Efficacy and Safety of Sotrovimab Versus Oral Antiviral for Early Treatment in High-Risk Patients in Omicron Era: A Multicenter Retrospective Study. Pathogens, 14(3), 216.
https://doi.org/10.3390/pathogens14030216
